Advertisement


Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective

2016 San Antonio Breast Cancer Symposium

Advertisement

Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.



Related Videos

Breast Cancer

Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives

Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.

Breast Cancer
Genomics/Genetics

Nikhil Wagle, MD, on Breast Cancer: Advances in Genomics

Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).

Breast Cancer

Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42

Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).

Symptom Management
Breast Cancer

Jame Abraham, MD, on Hair Loss: SCALP Trial Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).

Breast Cancer

Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel

Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).

Advertisement

Advertisement




Advertisement